PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Society for Cardiovascular Angiography and Interventions bestows highest designation ranking to leading interventional cardiologists

MSCAI recipients recognized during SCAI 2023 Scientific Sessions in Phoenix

2023-05-21
(Press-News.org) PHOENIX (May 20, 2023) – Today, the Society for Cardiovascular Angiography & Interventions (SCAI) announced its 2023 Master Interventionalists of SCAI (MSCAI) designation recipients during the SCAI 2023 Scientific Sessions in Phoenix.

The MSCAI designation is awarded to individuals who have demonstrated excellence in invasive/interventional cardiology over the course of their career and for their commitment to the highest levels of clinical care, innovation, publication, and teaching.

This year’s MSCAI designations were awarded to the following group of outstanding interventionalists:

David T. Balzer, MD, MSCAI
Dr. Balzer received his undergraduate degree in Biochemistry from the University of Missouri-Columbia. He attended medical school at St. Louis University School of Medicine and did his pediatrics residency at Cardinal Glennon Children's Hospital. He was a pediatrician in the Air Force for three years following his residency. He then did a cardiology fellowship at Washington University School of Medicine. He has been an attending physician at Washington University School of Medicine/St. Louis Children's Hospital since completion of his fellowship. He is currently Director of the Cardiac Cath Lab at St. Louis Children's Hospital. He has been actively involved in teaching and research for 30 years and has been institutional principal investigator on numerous multi-center device trials.

Ronald P. Caputo, MD, MSCAI
Dr. Caputo graduated from Georgetown University with a BS in Biology and a minor in English and subsequently graduated from Georgetown University Medical School. He completed his residency in internal medicine at the University of Massachusetts Medical Center and stayed on as Chief Medical
Resident. Following this, he moved on to the Harvard/Beth Israel Cardiology program completing general and interventional cardiology training. He was privileged to work there with Drs Donald Baim, William Grossman, Richard Kuntz, David Cohen, Joseph Carrozza, Mark Josephson, and many others - all of whom motivated him to strive for excellence in the field. Moving on to a busy clinical interventional cardiology practice with St. Joseph's Hospital Cardiology Associates, he helped pioneer radial arterial access, doing his first radial cases in 1997. He developed a clinical research program that was proud to participate in several seminal clinical device studies, and he is an author of more than 90 peer-reviewed manuscripts. He moved on to start a cardiovascular service line at Physician's Regional Medical Center in Naples, FL helping to initiate cardiothoracic surgery, high-risk PCI, structural heart and PERT programs, and clinical research. Interest in new devices prompted the formation of two medical device companies (AngioLink and Transluminal Technologies), within which he has several issued patents and two medical devices that have received regulatory approval. He is a strong advocate for SCAI, having served on the Board of Trustees, as the Chairman of the Membership Committee, and as a member of the Industrial
Relations Committee for many years.

Shao-Liang Chen, MD, MSCAI
Dr. Shao-Liang Chen, MD, PhD, is an interventional cardiologist in Nanjing First Hospital (Center of Excellence by European Heart Journal), Nanjing Medical University, Nanjing, China. Dr. Chen has published 300+ original papers and is highly cited clinician-scientist in China. Coronary intervention
(particularly left main and bifurcation stenting, intravascular imaging, and physiological assessment, etc.), pulmonary arterial hypertension, and biological molecular science are Dr. Chen's major, with a total of PCI cases > 10,000 and annual PCI number > 500 cases.

Tarek Helmy, MD, MSCAI
Dr. Tarek Helmy is the Division Chief of Cardiology. He completed his interventional fellowship training from New England Medical Center, Tufts University. He has been on the faculty at Emory University School of Medicine, University of Cincinnati College of Medicine, and Saint Louis School of Medicine. His interests include complex coronary intervention, CTO and structural heart disease. His research interests are in coronary physiology.

Eric Horlick, MD, MSCAI
Dr. Horlick is an adult interventional cardiologist specializing in structural and adult congenital heart disease at the Toronto General Hospital. Eric completed medical school, internal medicine and cardiology at McGill University and then did fellowship training in PCI and ACHD intervention at the
Toronto General Hospital and never left. He was "structural" long before this name was used commonly. He was named the Inaugural Peter Munk Chair in Structural Heart Disease in 2015 and rose to the rank of Professor of Medicine in 2018. Eric has trained 32 fellows in structural and congenital heart disease from six continents and many more angioplasty fellows. He has mentored the research of graduate students, cardiology residents, medical
residents, and students. Over a dozen of his undergraduate research students would go on to attend medical school. He has over 190 publications and has given over 400 invited lectures internationally. Eric worked with SCAI colleagues on the Fellows Courses and as a representative on multiple multi-society documents. Eric co-founded the Canadian Network for Adult Congenital Heart Disease Intervention Research, is a CIHR-funded investigator and clinical trialist.

Alexandra J. Lansky, MD, MSCAI
Alexandra J. Lansky, MD, is Professor of Medicine in the section of Cardiology at the Yale School of Medicine and a practicing cardiologist at Yale-New Haven Hospital, in New Haven, CT. From 2004 to 2010, Dr. Lansky was Associate Professor of Medicine at Columbia University College of Physicians and Surgeons, Director of Clinical Services at the Center for Interventional Vascular Therapy, a practicing cardiologist at New York-Presbyterian, and Chief Scientific Officer of the Cardiovascular Research Foundation Clinical Trials Center. Prior to that, she was an interventional cardiologist on faculty at
Washington Hospital Center in Washington, DC, and at Lenox Hill Hospital in New York, NY.

She has dedicated her career to leading clinical and angiographic evaluations of more than 500 clinical trials in a broad range of ischemic cardiovascular therapeutic areas, including pharmacologic and interventional device trials, many of which are landmark trials in the field and/or leading to FDA approval in the United States. She has served as the principal investigator on numerous national and international imaging studies, device, DES, and neuroprotection trials. Dr. Lansky has authored and coauthored over 500 academic peer-reviewed manuscripts in the fields of interventional cardiology, angiography, and women’s cardiovascular health. She chaired the American Heart Association Statement on Interventions in Women and most recently the Academic Research Consortium defining Neurologic Endpoints in clinical cardiovascular trials.

Dr. Lansky has been recognized for her clinical research contributions with several prestigious awards including Master of Arts Privatim from Yale University in 2017; Top Doctors in Connecticut in 2017, Thompson Reuter’s 2014 and 2016 “Most Influential Scientific Minds for Clinical Medicine”; 2012 Wenger Award of Clinical Excellence in Women’s Health, Visiting Professor at Fu Wai Hospital, Bejing, China, and Honorary Professor, University College London. Dr. Lansky is board certified in cardiovascular diseases. A graduate of the Medical College of Virginia in Richmond, VA, she received her residency training in internal medicine, cardiology, and interventional cardiology at Washington Hospital Center, Washington DC. Dr. Lansky is a Fellow of the European Society of Cardiology, the American College of Cardiology, the American Heart Association, and the Society of Cardiovascular Angiography and Interventions.

Debabrata Mukherjee, MD, MSCAI
Debabrata Mukherjee, MD, MS, is a Professor and Chairman of the Department of Internal Medicine at the Texas Tech University Health Sciences Center in El Paso, Texas. Before this, he held the position of the Gill Foundation Professor of Interventional Cardiology, and the Director of the Cardiac
Catheterization Laboratory at the University of the Kentucky and the Director of the Peripheral Interventional Program at the University of Michigan. Dr. Mukherjee completed his residency training in internal medicine at the Cleveland Clinic Foundation. Subsequently, he completed a fellowship in
cardiovascular medicine and interventional cardiology also at the Cleveland Clinic Foundation. Dr. Mukherjee also completed a Masters in Clinical Research (MS) at the University of Michigan and a Certificate in Business Administration at the University Of Kentucky Gatton College Of Business.

Dr. Mukherjee has received the American College of Cardiology (ACC) Career Development Grant, the Joseph Cash Memorial Award for excellence in Health outcome research, and the Cardiovascular Center McKay Research Grant for Peripheral Arterial Disease. He has been named as one of the Best Doctors in America for several years. Dr. Mukherjee has been an invited lecturer at several major national and international meetings, has authored over 600 publications with an H-index of 80 (Google Scholar), edited 19 textbooks on cardiovascular diseases, and has written more than 100 textbook chapters. He serves on several journal editorial boards and is an Associate Editor for Cardiosource (ACC.org). He is a long-standing fellow of the American College of Cardiology, the American Heart Association, the Society for Vascular Medicine & Biology, and very importantly, the Society for Cardiac Angiography and Interventions. In 2020, Dr. Mukherjee received the American College of Cardiology Distinguished Fellowship Award for his extensive work as a clinician, educator, and scientist.

Samir B. Pancholy, MD, MSCAI
Dr. Samir B. Pancholy practices in Scranton, PA, and serves as the Founding Program Director of the fellowship program in cardiovascular diseases at The Wright Center for Graduate Medical Education, as Professor of Medicine at the Geisinger Commonwealth School of Medicine, and as Director of
Interventional Cardiology at the Veterans Administration Medical Center, Wilkes-Barre, PA.

He earned his medical degree from BJ Medical College in Ahmedabad, India, and completed his residency at the State University of New York, Stony Brook, NY. In addition, Dr. Pancholy completed fellowships in cardiovascular disease and interventional cardiology at the Presbyterian Medical Center
and Medical College of Pennsylvania in Philadelphia, PA.

While practicing in a community setting, Dr. Pancholy has authored over 150 peer-reviewed manuscripts in reputed international journals and several textbooks. His pragmatic research questions, passion, and energy have motivated several like-minded investigators globally, resulting in several practice-changing randomized trials, providing foundational evidence that has led to the development of best practice recommendations for transradial procedures. He has developed multiple techniques to improve procedural safety and success while performing catheter-based procedures. He has invented several medical devices, some FDA-approved and used in cardiac catheterization laboratories worldwide. He holds more than 70 patents issued by the United States Patent and Trademark Office. He is the Founding Co-Chair of the Transradial Working Group and Vascular Access Working Group of
SCAI, credited with a successful and systematic campaign to increase the adoption of transradial access in the US and globally. He is the founding chair of the SCAI-TRIP (Transradial Intervention Program), providing educational programs in transradial access. In addition, he is the Founding Co-Director of the Transradial Interventional Course (TRICO) offered annually in Ahmedabad, India. since 2006, providing a live demonstration platform portraying state-of-the-art PCI techniques, with an emphasis on transradial access.

###

About SCAI
The Society for Cardiovascular Angiography & Interventions (SCAI) is a non-profit professional association with over 4,500 members representing interventional cardiologists and cardiac catheterization teams in the United States. SCAI promotes excellence in interventional cardiovascular
medicine for both adults and children through education, representation, and the advancement of quality standards to enhance patient care. Follow @SCAI on Twitter for the latest heart health news.

END


ELSE PRESS RELEASES FROM THIS DATE:

HRS, APHRS, and LAHRS release cardiac physiological pacing guideline

2023-05-20
New Orleans, May 20, 2023 – Today, the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Latin American Heart Rhythm Society (LAHRS) released a new clinical practice guideline on cardiac physiologic pacing (CPP) strategies to restore ventricular synchrony and improve cardiac performance. The 2023 HRS/APHRS/LAHRS Guideline on Cardiac Physiologic Pacing for the Avoidance and Mitigation of Heart Failure is intended to provide guidance to clinical cardiac electrophysiologists, cardiologists, and other clinicians on the use of CPP, which includes cardiac resynchronization therapy and conduction system pacing, in patients ...

Tokyo Tech and HPE collaborate to build the next generation TSUBAME4.0 supercomputer for artificial intelligence, scientific research, and innovation

Tokyo Tech and HPE collaborate to build the next generation TSUBAME4.0 supercomputer for artificial intelligence, scientific research, and innovation
2023-05-20
Tokyo Institute of Technology (Tokyo Tech) Global Scientific Information and Computing Center (GSIC) and Hewlett Packard Enterprise (NYSE: HPE) announced to build its next-generation supercomputer, TSUBAME4.0, to accelerate AI-driven scientific discovery in medicine, materials science, climate research, and turbulence in urban environments. Tokyo Tech is one of the world's leading universities in science and technology. With the TSUBAME4.0 supercomputer, users will have the ability to train ...

Heart attack patients with strong legs have better prognosis

2023-05-20
Prague, Czechia – 20 May 2023:  People with strong legs are less likely to develop heart failure after a heart attack, according to research presented today at Heart Failure 2023, a scientific congress of the European Society of Cardiology (ESC).1 Myocardial infarction is the most common cause of heart failure,2 with around 6–9% of heart attack patients going on to develop the condition.3,4 Previous research has shown that having strong quadriceps is associated with a lower risk of death in patients with coronary artery disease.5 This study tested ...

Remote monitoring reduces heart failure hospitalizations and improves quality of life

2023-05-20
Prague, Czechia – 20 May 2023:  The first investigator-initiated study of remote pulmonary artery pressure monitoring has found that it improves quality of life and reduces heart failure hospitalisations in patients with chronic heart failure. The findings are presented today in a late breaking science session at Heart Failure 2023, a scientific congress of the European Society of Cardiology (ESC),1 and published in The Lancet. Principal investigator Dr. Jasper Brugts of Erasmus University Medical Centre, ...

A Spanish team presents the first pharmacological treatment able to improve cardiac function in stiff-heart syndrome

A Spanish team presents the first pharmacological treatment able to improve cardiac function in stiff-heart syndrome
2023-05-20
Transthyretin-related cardiac amyloidosis is a progressive disease characterized by the deposition of amyloid protein fibrils in the heart. Amyloid fibril deposition thickens and stiffens the heart walls, and the disease is also known as stiff-heart syndrome. The accumulation of amyloid fibrils causes heart failure, and patients suffer from fluid retention, fatigue, and arrhythmias. The disease can be caused by genetic mutations or related to aging. Prognosis is poor, and untreated patients survive for an average of just 3 years. Now, the ...

George Dangas, MD, Ph.D., named President of Society for Cardiovascular Angiography & Interventions

George Dangas, MD, Ph.D., named President of Society for Cardiovascular Angiography & Interventions
2023-05-20
The Society for Cardiovascular Angiography & Interventions (SCAI) has named George Dangas, MD, PhD, Professor of Medicine (Cardiology), and Surgery, at the Icahn School of Medicine at Mount Sinai as its new President. He was appointed on Saturday, May 20, during the closing ceremonies at the SCAI 2023 Scientific Sessions in Phoenix. He is the first Mount Sinai cardiologist to hold this position and will serve as the 46th President of SCAI. Dr. Dangas, also the Director of Cardiovascular Innovation at the Zena and Michael A. Wiener Cardiovascular Institute at Icahn Mount Sinai and Chief of Cardiology ...

Forging partnerships in the Americas: Naval leaders gather at SIANC S&T Conference

Forging partnerships in the Americas: Naval leaders gather at SIANC S&T Conference
2023-05-20
ARLINGTON, Va.—For Dr. Brett Seidle — the deputy assistant secretary of the Navy for Research, Development, Test and Engineering — the breakneck speed of current scientific progress and technological proliferation can be challenging, especially when the impact of new technologies on civilian and military realities transcends national borders. While giving the keynote address at the recent Specialized Inter-American Naval Conference on Science, Technology and Innovation (SIANC-ST&I) in Orlando, Florida, Seidle identified several scientific disciplines that have developed into ...

New study reveals possible future health impacts related to climate mitigation

2023-05-20
UNIVERSITY PARK, Pa. — Reduce fossil fuel use and air quality will improve, right? It might not be as straightforward as it appears, according to a Penn State-led research team. They explored almost 30,000 simulated future scenarios and found that some climate mitigation efforts could lead to harmful health impacts in certain geographic areas.  Their results were published today (May 18) in Nature Sustainability.  “In general, reducing fossil fuel use is good for climate mitigation and good for cleaning up the air, and the modeling studies have always found health benefits from climate mitigation,” said corresponding ...

Study finds cardiovascular risk score improves after one year of semaglutide use in patients with overweight and obesity

2023-05-20
New research presented at this year’s European Congress on Obesity in Dublin, Ireland shows that patients treated with the obesity drug semaglutide have a decreased cardiovascular risk score after one year of use. The study is by Dr Andres Acosta and Dr Wissam Ghusn, Precision Medicine for Obesity Program at the Mayo Clinic, Rochester, MN, USA and colleagues. Obesity is a major risk factor for the development of abnormal blood fat levels, type-2 diabetes mellitus (T2DM), high blood pressure, and obstructive sleep apnoea. These comorbidities are associated with an increased risk of cardiovascular disease (CVD) that represents ...

Semaglutide shown to be effective for weight loss in multicentre, one-year real-world study

2023-05-20
New research presented at this year’s European Congress on Obesity (ECO2023, Dublin, 17-20 May) shows that the obesity drug semaglutide is effective for weight loss in a multicentre, 1-year-long real-world study. The study is by Dr Andres Acosta and Dr Wissam Ghusn, Precision Medicine for Obesity Program at the Mayo Clinic, Rochester, MN, USA and colleagues. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the most recently FDA-approved anti-obesity medication. It has shown significant weight loss outcomes in multiple long-term randomised clinical trials and short-term real-world studies. However, little is known about ...

LAST 30 PRESS RELEASES:

Call for papers: 14th Asia-Pacific Conference on Transportation and the Environment (APTE 2025)

A novel disturbance rejection optimal guidance method for enhancing precision landing performance of reusable rockets

New scan method unveils lung function secrets

Searching for hidden medieval stories from the island of the Sagas

Breakthrough study reveals bumetanide treatment restores early social communication in fragile X syndrome mouse model

Neuroscience leader reveals oxytocin's crucial role beyond the 'love hormone' label

Twelve questions to ask your doctor for better brain health in the new year

Microelectronics Science Research Centers to lead charge on next-generation designs and prototypes

Study identifies genetic cause for yellow nail syndrome

New drug to prevent migraine may start working right away

Good news for people with MS: COVID-19 infection not tied to worsening symptoms

Department of Energy announces $179 million for Microelectronics Science Research Centers

Human-related activities continue to threaten global climate and productivity

Public shows greater acceptance of RSV vaccine as vaccine hesitancy appears to have plateaued

Unraveling the power and influence of language

Gene editing tool reduces Alzheimer’s plaque precursor in mice

TNF inhibitors prevent complications in kids with Crohn's disease, recommended as first-line therapies

Twisted Edison: Bright, elliptically polarized incandescent light

Structural cell protein also directly regulates gene transcription

Breaking boundaries: Researchers isolate quantum coherence in classical light systems

Brain map clarifies neuronal connectivity behind motor function

Researchers find compromised indoor air in homes following Marshall Fire

Months after Colorado's Marshall Fire, residents of surviving homes reported health symptoms, poor air quality

Identification of chemical constituents and blood-absorbed components of Shenqi Fuzheng extract based on UPLC-triple-TOF/MS technology

'Glass fences' hinder Japanese female faculty in international research, study finds

Vector winds forecast by numerical weather prediction models still in need of optimization

New research identifies key cellular mechanism driving Alzheimer’s disease

Trends in buprenorphine dispensing among adolescents and young adults in the US

Emergency department physicians vary widely in their likelihood of hospitalizing a patient, even within the same facility

Firearm and motor vehicle pediatric deaths— intersections of age, sex, race, and ethnicity

[Press-News.org] Society for Cardiovascular Angiography and Interventions bestows highest designation ranking to leading interventional cardiologists
MSCAI recipients recognized during SCAI 2023 Scientific Sessions in Phoenix